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Aim
In resource-limited countries, NNRTI-based regimen
may result in emergence of more HIV drug resistance
because of a low genetic barrier. We compare the effi-
cacy and tolerance of LPV/r and NVP-based regimens
and 2 WHO nucleoside backbones in naive HIV
infected patients (p.).
Materials and methods
Naive p. from 5 clinics in Lubumbashi (Congo-DRC) were
randomized to receive LPV/r versus NVP combined with
TDF/FTC or ZDV/3TC. VL and CD4 were performed at
baseline (BL) and every 24 weeks (W). The primary end-
point was the % of p. with therapeutic failure defined as
clinical and virologic failures (VL>1000 c/ml)(missing
data=failure), assessed at W48 and 96. We present here
the results of 144 W of follow-up.
Results
425 Black African p. (72% female; median (md) age
38 years, md CD4 165/µL; md VL 5.2 log c/ml) were ran-
domized (216 in LPV/r, 209 in NVP). BL characteristics
were comparable. In the ITT analysis, previous results
showed no difference between LPV/r and NVP treatment
arms at W96 except a higher proportion of virologic fail-
ure (VF) in p. on NVP-based regimens. W144 ITT analysis
showed a significant difference on endpoints between
LPV/r (94/216) and NVP (111/209)(p=0.0479) and persis-
tence of a significant difference in VF rate (20/216 vs
37/209 for LPV/r and NVP, respectively)(p= 0.015). BL
genotypes showed NNRTI mutations (mt) in 3/31 NVP-
failing p. and no PI mt in LPV/r-failing patients. At time
of failure, NNRTI mt were seen in 23/26 NVP-failing
p. and 0/13 primary PI mt in LPV/r failing patients. NRTI
mt were seen in 19/26 p. in NVP arm (including K65R in
7p. and M184V in 18p.) vs 3/13p. in LPV/r arm (M184V
in 3p.).
Md CD4 change from BL was significant higher in LPV/
r arm (251 cells/µL [interquartile range (IQR) 153;384])
compared with NVP arm (174 cells/µL [IQR 102-330])(p=
0.0093). Percentage of p. with adherence >95% was similar
(73.6 vs 74.4 for LPV/r vs NVP).
Conclusions
In a resource-limited setting after 144 weeks of follow-up
NNRTI-NRTI first-line regimen is associated with more
virologic failure, more drug resistance mutations and a
lower immunologic response than a PI-based regimen.
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